investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Defining the impact of clonal evolution on chronic lymphocytic leukemia
Catherine Ju-Ying Wu
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Catherine Ju-Ying Wu
Dana-Farber Cancer Institute
Boston, United States
Related projects
Julie Aurore Losman
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
Leukaemia
John D Schuetz
Metabolic pathways in leukemia
Leukaemia
Reuben Kapur
Role of p21 Activated Kinase in Leukemogenesis
Leukaemia
Hematology and hematologic malignancies
David A Williams
Rac proteins in hematopoietic cell survival and function
Leukaemia
Hematology and hematologic malignancies
Kim O'Neill
Cancer Immunology Research at Brigham Young University
Leukaemia
Nora C Heisterkamp
Role of Sialic Acid Modification in ALL Survival and Drug Resistance
Leukaemia
Pathology
Hematology and hematologic malignancies
Kenneth Lynn Wright
Natural Killer Cell Regulation by PRDM1 and IRF4/8
Leukaemia
Scott W Lowe
The impact of chromosome 17p lesions on leukemogeneis and therapy response
Leukaemia
Pathology
Hematology and hematologic malignancies
David FitzGerald
Bio-Therapies for the Treatment of Cancer
Leukaemia